Dr. Dome is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Ave NW
, WW 2.5-500
Washington, DC 20010Phone+1 202-476-2800Fax+1 202-476-5685
Summary
- Dr. Jeffrey Dome is a pediatric oncologist and Senior Vice President of the Center for Cancer and Blood Disorders at Children's National Hospital in Washington, DC. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania, completed pediatrics residency at Yale New-Haven Hospital, and completed a fellowship in hematology/oncology at Johns Hopkins Hospital. He is internationally recognized for his expertise on pediatric solid tumors, including kidney tumors, bone tumors, and sarcomas. He serves on the Scientific Council of the Children's Oncology Group and is president of the North America Continental Branch of the International Society of Pediatric Oncology (SIOP). He has published more than 200 articles, chapters, and letters on pediatric cancer.
Education & Training
- Erasmus UniversityPhD, Medicine, 2008 - 2009
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1994 - 1997
- Yale-New Haven Medical CenterResidency, Pediatrics, 1991 - 1994
- Perelman School of Medicine at the University of PennsylvaniaClass of 1991
Certifications & Licensure
- MD State Medical License 1994 - 2026
- VA State Medical License 2006 - 2026
- DC State Medical License 2006 - 2024
- TN State Medical License 1997 - 2007
- CT State Medical License 1993 - 1994
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2012-2013
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
- Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
- Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 18 citationsOutcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.Hannah Kinoshita, Kenneth R Cooke, Melanie Grant, Maja Stanojevic, C Russell Cruz
Blood Advances. 2022-04-26 - 81 citationsTelomerase Expression Predicts Unfavorable Outcome in OsteosarcomaRobert P. Sanders, Rachid Drissi, Catherine A. Billups, Najat C. Daw, Marcus B. Valentine
Journal of Clinical Oncology. 2004-09-15 - 112 citationsDevelopment and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomeraseKeichiro Mihara, Chihaya Imai, Elaine Coustan-Smith, Jeffrey S. Dome, Massimo Dominici
British Journal of Haematology. 2003-03-01
Press Mentions
- Johns Hopkins Medicine Celebrates Opening of the Johns Hopkins National Proton Center at Sibley Memorial Hospital, in Collaboration with Children’s NationalOctober 28th, 2019
- Couple Remembers Late Son by Passing Out Sweets and Treats at Children's National Health SystemMay 18th, 2019
- Kymriah Treatment Available at Children’s National Health SystemApril 16th, 2019
- Join now to see all
Grant Support
- Development and Conduct of Children's Oncology Group Clinical TrialsNIH2023–2028
- Telomere Maintenance Mechanisms In Human OsteosarcomaNational Cancer Institute2006
- Telomerase As A Prognostic Indicator For Wilms TumorNational Cancer Institute2000–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: